Replacing Finger Stick? DexCom Says Its Latest CGM Data Is A Key Step
This article was originally published in The Gray Sheet
Executive Summary
Continuous glucose monitor firm DexCom has defined 10 percent accuracy compared to a lab reference as the crucial target to support its monitors as outright replacements for patient self-monitoring to inform insulin dosing. It has now met that goal in an initial study, but pivotal data will be needed to convince FDA.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.